Overview
What is Stichting Tuberculosis Vaccine Initiative?
Stichting Tuberculosis Vaccine Initiative is a nonprofit organization situated in Lelystad, Netherlands. Their primary focus is mobilizing resources and managing projects related to tuberculosis (TB) vaccine research and development. They have a strong emphasis on early-stage activities such as discovery, preclinical, and initial clinical studies. Additionally, they support projects to optimize, validate biomarkers and work collaboratively with governments, foundations, and the private sector to secure public funding and private investment opportunities for the advancement of new TB vaccine research. Their mission is to integrate, translate, and prioritize R&D efforts to develop accessible and affordable TB vaccines for all.
Official website here: www.tbvi.eu
Is Stichting Tuberculosis Vaccine Initiative legitimate?
Stichting Tuberculosis Vaccine Initiative is a legitimate nonprofit organization registered as a 501(c)(3) entity. Stichting Tuberculosis Vaccine Initiative submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $369,885
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.tbvi.eu
What is the mission statement of Stichting Tuberculosis Vaccine Initiative?
The mission of Stichting Tuberculosis Vaccine Initiative is centered around supporting and prioritizing research and development efforts to discover and create new tuberculosis vaccines that are both accessible and affordable for all individuals worldwide. The organization plays a significant role in mobilizing resources, identifying, developing, and managing projects related to TB vaccine research, with a focus on discovery, preclinical, and early clinical activities. Additionally, TBVI works on projects for the optimization and validation of biomarkers and collaborates with various entities such as governments, foundations, and the private sector to increase public funding and private sector investment opportunities for the development of new TB vaccines.
Official website here: www.tbvi.eu
Who is the CEO of Stichting Tuberculosis Vaccine Initiative?
Anne Meinema is the Director External Relations And Res of Stichting Tuberculosis Vaccine Initiative.
Official website here: www.tbvi.eu
What is the revenue of Stichting Tuberculosis Vaccine Initiative?
Stichting Tuberculosis Vaccine Initiative's revenue in 2022 was $839,289.
Official website here: www.tbvi.eu
Who are the executives of Stichting Tuberculosis Vaccine Initiative and what are their salaries?
Here are 6 key members and their salaries:
- Compensation: $20,926
- Related: $0
- Other: $0
- Compensation: $34,755
- Related: $0
- Other: $0
- Compensation: $128,997
- Related: $0
- Other: $0
- Compensation: $26,248
- Related: $0
- Other: $0
- Compensation: $54,823
- Related: $0
- Other: $0
- Compensation: $86,874
- Related: $0
- Other: $0
Official website here: www.tbvi.eu
Where can I find the form 990 for Stichting Tuberculosis Vaccine Initiative?
Stichting Tuberculosis Vaccine Initiative's most recent form 990 was submitted in 2022 and can be accessed here.
Official website here: www.tbvi.eu
Learn more at the official website: www.tbvi.eu
Mission Statement of Stichting Tuberculosis Vaccine Initiative
Stichting Tuberculosis Vaccine Initiative, abbreviated as TBVI, is dedicated to supporting and facilitating the integration, translation, and prioritization of research and development (R&D) efforts aimed at discovering and developing new tuberculosis (TB) vaccines. The organization's mission is to ensure that these vaccines are not only accessible but also affordable for all individuals worldwide.
TBVI plays a crucial role in mobilizing resources and managing projects focused on TB vaccine R&D, with a strong emphasis on discovery, preclinical, and early clinical activities. The organization also supports projects that aim to discover, optimize, and validate biomarkers. To advance its mission, TBVI collaborates with various stakeholders, including governments, foundations, and the private sector, with the primary objective of increasing public funding and private sector investment opportunities for the R&D of new TB vaccines.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Stichting Tuberculosis Vaccine Initiative (TBVI) plays a crucial role in advancing the development of new tuberculosis vaccines. By mobilizing resources and managing projects focused on vaccine research and development, TBVI addresses the pressing need for effective TB vaccines that are both accessible and affordable.
The organization prioritizes research efforts in the discovery, preclinical, and early clinical phases, ensuring that innovative approaches are effectively translated into viable vaccine candidates. TBVI also emphasizes the importance of biomarkers, actively supporting projects aimed at their discovery, optimization, and validation. This focus not only enhances the vaccine development process but also facilitates the identification of effective diagnostic tools.
Collaborating with governments, foundations, and the private sector, TBVI works to amplify public and private investment in tuberculosis vaccine R&D. Through these partnerships, the initiative fosters a collaborative environment aimed at overcoming the challenges of TB, a disease that continues to pose significant global health risks.
Ultimately, TBVI’s impact lies in its commitment to integrating research efforts and translating scientific advancements into practical solutions, contributing to the global fight against tuberculosis and helping to ensure that new vaccines reach those who need them most.
This information is meant to be a general summary of Stichting Tuberculosis Vaccine Initiative. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Investment Income: $785
- Gross Receipts: $839,289
Assets and Liabilities:
- Total Assets: $2,068,439
- Total Liabilities: $1,997,217
- Net Assets: $71,222
Want to help this charity, for free? You can click here to learn more about Give Freely
Organization Details
Founding Year
2008
Phone
0320277551Principal Officer
Anne Meinema
Website
www.tbvi.euNTEE Category
Code: H124 - Medical research
If you are a representative of Stichting Tuberculosis Vaccine Initiative and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.